These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 33179146)

  • 1. Healthcare Cost and Utilization Associated with Biologic Treatment Patterns Among Patients with Psoriatic Arthritis: Analyses from a Large US Claims Database.
    Hur P; Kim N; Dai D; Piao OW; Zheng JZ; Yi E
    Drugs Real World Outcomes; 2021 Mar; 8(1):29-38. PubMed ID: 33179146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health care utilization and cost associated with switching biologics within the first year of biologic treatment initiation among patients with ankylosing spondylitis.
    Yi E; Dai D; Piao OW; Zheng JZ; Park Y
    J Manag Care Spec Pharm; 2021 Jan; 27(1):27-36. PubMed ID: 33043820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health Care Utilization and Cost Associated with Biologic Treatment Patterns Among Patients with Moderate to Severe Psoriasis: Analyses from a Large U.S. Claims Database.
    Feldman SR; Tian H; Wang X; Germino R
    J Manag Care Spec Pharm; 2019 Apr; 25(4):479-488. PubMed ID: 30556761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world evaluation of TNF-inhibitor utilization in rheumatoid arthritis.
    Harnett J; Wiederkehr D; Gerber R; Gruben D; Koenig A; Bourret J
    J Med Econ; 2016; 19(2):91-102. PubMed ID: 26401963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Outcomes Associated with Switching or Discontinuation from Anti-TNF Inhibitors for Nonmedical Reasons.
    Wolf D; Skup M; Yang H; Fang AP; Kageleiry A; Chao J; Mittal M; Lebwohl M
    Clin Ther; 2017 Apr; 39(4):849-862.e6. PubMed ID: 28363696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriatic arthritis: results from a US claims analysis.
    Wu JJ; Pelletier C; Ung B; Tian M
    Curr Med Res Opin; 2020 Jan; 36(1):169-176. PubMed ID: 31517542
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment patterns and health care costs for patients with psoriatic arthritis on biologic therapy: a retrospective cohort study.
    Zhu B; Edson-Heredia E; Gatz JL; Guo J; Shuler CL
    Clin Ther; 2013 Sep; 35(9):1376-85. PubMed ID: 23954091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healthcare resource use and costs of privately insured patients who switch, discontinue, or persist on anti-muscarinic therapy for overactive bladder.
    Ivanova JI; Hayes-Larson E; Sorg RA; Birnbaum HG; Berner T
    J Med Econ; 2014 Oct; 17(10):741-50. PubMed ID: 25051328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The economic burden of switching targeted disease-modifying anti-rheumatic drugs among rheumatoid arthritis patients.
    Shahabi A; Shafrin J; Zhao L; Green S; Curtice T; Marshall A; Paul D
    J Med Econ; 2019 Apr; 22(4):350-358. PubMed ID: 30653389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system.
    Rashid N; Lin AT; Aranda G; Lin KJ; Guerrero VN; Nadkarni A; Patel C
    J Med Econ; 2016 Jun; 19(6):568-75. PubMed ID: 26766553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching of biologic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis in a real world setting.
    Meissner B; Trivedi D; You M; Rosenblatt L
    J Med Econ; 2014 Apr; 17(4):259-65. PubMed ID: 24575891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic Burden of Switching to Different Biologic Therapies Among Tumor Necrosis Factor Inhibitor-Experienced Patients with Psoriatic Arthritis.
    Song Y; Betts KA; Lu Y; Singh R; Clewell J; Griffith J
    Rheumatol Ther; 2019 Jun; 6(2):285-297. PubMed ID: 31055779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Healthcare utilization and costs among patients with psoriasis and psoriatic arthritis in the USA-a retrospective study of claims data from 2009 to 2020.
    Merola JF; Dennis N; Chakravarty SD; Villacorta R; Mesana L; Lin I; Wang Y; Shawi M; Pacou M; Baker T; Peterson S
    Clin Rheumatol; 2021 Oct; 40(10):4061-4070. PubMed ID: 33934270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Retrospective Cohort Study Comparing Utilization and Costs of Biologic Therapies and JAK Inhibitor Therapy Across Four Common Inflammatory Indications in Adult US Managed Care Patients.
    Chastek B; White J; Van Voorhis D; Tang D; Stolshek BS
    Adv Ther; 2016 Apr; 33(4):626-42. PubMed ID: 26970958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.
    Chastek B; Chen CI; Proudfoot C; Shinde S; Kuznik A; Wei W
    Adv Ther; 2017 Nov; 34(11):2422-2435. PubMed ID: 29039054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost of biologic treatment persistence or switching in rheumatoid arthritis.
    Gu T; Mutebi A; Stolshek BS; Tan H
    Am J Manag Care; 2018 Jul; 24(8 Spec No.):SP338-SP345. PubMed ID: 30020745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct healthcare costs and comorbidity burden among patients with psoriatic arthritis in the USA.
    Merola JF; Herrera V; Palmer JB
    Clin Rheumatol; 2018 Oct; 37(10):2751-2761. PubMed ID: 30051284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health Care Resource Utilization and Costs Associated With Switching Biologics in Rheumatoid Arthritis.
    Vanderpoel J; Tkacz J; Brady BL; Ellis L
    Clin Ther; 2019 Jun; 41(6):1080-1089.e5. PubMed ID: 31122662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic impact of biologic utilization patterns in patients with psoriatic arthritis.
    Schwartzman S; Li Y; Zhou H; Palmer JB
    Clin Rheumatol; 2017 Jul; 36(7):1579-1588. PubMed ID: 28474139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Healthcare Resource Use and Direct Costs in Patients with Ankylosing Spondylitis and Psoriatic Arthritis in a Large US Cohort.
    Greenberg JD; Palmer JB; Li Y; Herrera V; Tsang Y; Liao M
    J Rheumatol; 2016 Jan; 43(1):88-96. PubMed ID: 26628601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.